Whitening composition containing peony seed oil ceramide and application thereof

Abstract

The invention provides a whitening composition containing peony seed oil ceramide and application of the whitening composition, and relates to the technical field of cosmetics. It is proved for the first time that peony seed oil ceramide has the anti-inflammatory soothing and whitening effects, anti-inflammatory soothing can be achieved by reducing expression of NF-kappa B and release of inflammatory factors TNF-alpha and IL-6, and the problem that a traditional whitening agent is high in irritation is solved; the apparent chromaticity can be whitened, and the apparent brightness L * value is remarkably increased, so that the whitening effect is achieved. The peony seed oil ceramide is further compounded, it is proved that when the peony seed oil ceramide and multiple whitening agents are compounded, the whitening effect can be further enhanced, and the peony seed oil ceramide and the multiple whitening agents achieve the synergistic whitening effect.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a whitening composition comprising peony seed oil ceramide and an application thereof. Background Art

[0002] Human skin color is mainly composed of pigments such as melanin, pheomelanin and carotene, among which melanin is the main influencing substance. Among the current whitening cosmetics, the main products use epidermal exfoliants (fruit acids) or tyrosinase inhibitors (such as 377 (phenylethyl resorcinol), Vc, etc.) to achieve the effect of whitening and brightening. However, on the one hand, most of the current whitening products only study the production pathway of melanin, but ignore the fact that the skin as a whole biological organ requires comprehensive care in multiple dimensions to better achieve a healthy state of brightening and whitening. On the other hand, traditional whitening agents are prone to irritation to the skin, which is not conducive to widespread promotion.

[0003] Ceramide is an important component of the "brick wall" structure of the skin barrier and one of the important lipids in the stratum corneum, accounting for 50% of the lipids in the stratum corneum derived from the lamellar bodies in the granular cells. This lamellar body is distributed between the keratinocytes to form a barrier to prevent water loss. Ceramide is also a highly effective moisturizer. Its structure contains a large number of hydrophilic groups, which have a good affinity for water. It can promote epidermal hydration, reduce epidermal water evaporation, enhance epidermal cell cohesion, prevent skin dryness and desquamation, and play a key role in repairing the skin barrier. However, current research on ceramide mainly focuses on moisturizing and repairing effects, and little research on its whitening effect. Summary of the invention

[0004] The applicant of the present invention is the first to verify the whitening and anti-inflammatory soothing effects of ceramide in peony seed oil, and unexpectedly found in the study that by combining ceramide with traditional whitening agents, a synergistic effect can be achieved to enhance the whitening effect of the product. On this basis, a new whitening composition is proposed.

[0005] On the one hand, the present application provides the use of peony seed oil ceramide in anti-inflammatory, soothing and / or whitening.

[0006] Preferably, the peony seed oil ceramide is ceramide 3 derived from peony seed oil, and the preparation method thereof can refer to patent KR20170084950A.

[0007] On the other hand, the present application also provides a whitening composition, which comprises peony seed oil ceramide.

[0008] Furthermore, the concentration of the peony seed oil ceramide is 0.1%-3% by mass of the composition; preferably, 0.5%-1%.

[0009] The concentration of ceramide in peony seed oil can be any value among 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, and 3%.

[0010] Furthermore, the composition also includes a whitening agent; preferably, the whitening agent is selected from one or more of phenethylresorcinol, undecylenoylphenylalanine, nicotinamide, arbutin, and VC ethyl ether; more preferably, phenethylresorcinol and undecylenoylphenylalanine; preferably, the concentration of the whitening agent is 0.1%-5% by mass percentage of the composition; preferably, 0.3%.

[0011] The concentration of the whitening agent may be any value among 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, and 5%.

[0012] Furthermore, the composition further comprises auxiliary materials; preferably, the auxiliary materials comprise solvents, humectants, preservatives, thickeners, emulsifiers, oils, neutralizers, and polyols.

[0013] The composition of the present application may also be added with excipients, which may be appropriate solvents, emollients, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids, release retardants, etc.

[0014] In a preferred embodiment, the solvent may be water, the humectant may be one or more of glycerol, betaine, and trehalose, the preservative may be one or more of p-hydroxyacetophenone and 1,2-hexanediol, the thickener may be one or more of TR-1, the emulsifier may be one or more of SSE-20 and SS, the oil may be one or more of jojoba oil and squalane, the polyol may be butanediol, and the neutralizer may be arginine.

[0015] Among them, one or more kinds of moisturizers, preservatives, emulsifiers and oils can be used, and their specific proportions have no effect on the technical effect of the present application, so they are not further limited in the present application.

[0016] In a preferred embodiment, the composition includes: 1%-10% moisturizer, 1%-5% preservative, 0.1%-0.5% thickener, 0.1%-3% peony seed oil ceramide, 0.1%-1% emulsifier, 1%-5% oil, 0.1%-0.5% neutralizer, 1%-5% polyol, and 0.1%-5% whitening agent.

[0017] Preferably, the composition comprises 9% moisturizer, 1% preservative, 0.22% thickener, 0.5% peony seed oil ceramide, 0.7% emulsifier, 4.4% oil, 0.26% neutralizer, 3% polyol, 0.3% whitening agent, and the balance is water.

[0018] It can be understood by those skilled in the art that the above is only an example given in the present application, and those skilled in the art can select reagents with the same function for replacement according to actual conditions, as long as the technical solution of the present application can be completed.

[0019] The composition of the present application can be prepared by a general method, wherein one or more diluents or carriers can be added, for example, in the form of ointments, creams, emulsions, patches, facial masks and other commonly used dosage forms in the cosmetics field.

[0020] On the other hand, the present application also provides a method for preparing the whitening composition, which comprises: heating peony seed oil ceramide at 80°C-90°C, homogenizing at 2000-5000rpm for 1-5 minutes, cooling to below 70°C, homogenizing at 3000-7000rpm for 1-5 minutes, cooling to 25°C-40°C, and adding a whitening agent; preferably, the method comprises: heating peony seed oil ceramide at 85°C, homogenizing at 5000rpm for 5 minutes, cooling to below 65°C, homogenizing at 6000rpm for 3 minutes, cooling to 25°C, and adding a whitening agent.

[0021] In a preferred embodiment, the method comprises:

[0022] Heat the raw materials of phases A and B at 80℃-90℃, stir until they are evenly dispersed, mix phases A and B and homogenize at 2000-5000rpm for 1-5 minutes, cool to below 70℃, add phase C, homogenize at 3000-7000rpm for 1-5 minutes, cool to 25℃-40℃, add phase D, and stir evenly to obtain.

[0023] Phase A includes: solvent, humectant, preservative, thickener;

[0024] Phase B includes: peony seed oil ceramide, emulsifier, oil;

[0025] Phase C includes: solvent, neutralizer;

[0026] Phase D includes: whitening agent, polyol;

[0027] Wherein, the mass ratio of the C phase solvent to the A phase solvent is 2:(70-80); preferably, 2:75.62.

[0028] On the other hand, the present application also provides the use of peony seed oil ceramide in a whitening enhancer.

[0029] On the other hand, the present application also provides a whitening enhancer, which contains peony seed oil ceramide.

[0030] On the other hand, the present application also provides the use of the whitening enhancer in improving the whitening effect of a whitening agent; preferably, the whitening agent is selected from one or more of phenethylresorcinol, undecylenoylphenylalanine, niacinamide, arbutin, and VC ethyl ether; more preferably, phenethylresorcinol and undecylenoylphenylalanine.

[0031] On the other hand, the present application also provides the use of the whitening composition or the whitening enhancer in anti-inflammatory, soothing and / or whitening.

[0032] The present invention has the following beneficial effects:

[0033] 1. This application proves for the first time that ceramide derived from peony seed oil (i.e., peony seed oil ceramide) has anti-inflammatory, soothing and whitening effects. Specifically, it can achieve anti-inflammatory and soothing effects by reducing the expression of NF-κB and the release of inflammatory factors TNF-α and IL-6, avoiding the high irritation problem of traditional whitening agents, and can also whiten the apparent chromaticity and significantly increase the apparent brightness L* value, thereby exerting a whitening effect.

[0034] 2. In this application, peony seed oil ceramide is compounded with a variety of whitening agents, proving that compounding peony seed oil ceramide with a variety of whitening agents (377 or undecylenoyl phenylalanine) can further enhance the whitening effect, and the two play a synergistic whitening role. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0036] Figure 1 The NF-κB immunofluorescence staining images of each group in Example 1;

[0037] Figure 2 The apparent chromaticity diagrams of each group in Example 1 are shown below;

[0038] Figure 3 This is a statistical chart of the skin ITA° difference results between whitening composition 1# and whitening composition 2# in Example 2;

[0039] Figure 4 This is a statistical chart of the skin MI difference results of whitening composition 1# and whitening composition 2# in Example 2;

[0040] Figure 5 This is a statistical chart of the skin ITA° difference results between whitening composition 3# and whitening composition 4# in Example 2;

[0041] Figure 6 This is a statistical chart of the skin MI difference results of whitening composition 3# and whitening composition 4# in Example 2. DETAILED DESCRIPTION

[0042] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.

[0043] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0044] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0045] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0046] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention. The test methods in the following examples without specifying specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturers.

[0047] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0048] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in microbiology, biochemistry, analytical chemistry, cell culture, and related fields conventional in the technical field.

[0049] Among them, the preparation method of peony seed oil ceramide, i.e. ceramide 3 derived from peony seed oil, can refer to patent KR20170084950A.

[0050] Specifically, peony seed oil ceramide can be prepared by the following method:

[0051] 100 g of peony seed oil and 10 g of phytosphingosine were mixed in a beaker, and stirred at 100° C. for 3 h using a homogenizer at a stirring speed of 200 rpm to prepare an emulsified green ceramide composition, namely, peony seed oil ceramide.

[0052] The peony seed oil ceramide obtained above can also be separated and purified. The separation and purification method is to add 50 times hexane for precipitation and then obtain the precipitate by filtering.

[0053] In addition, the "water" mentioned in the present invention includes any feasible water that can be used in the art, such as deionized water, distilled water, ion exchange water, double distilled water, high-purity water, and purified water.

[0054] In the following examples, unless otherwise specified, % means wt %, i.e. weight percentage.

[0055] Example 1 Peony seed oil ceramide efficacy test

[0056] NF-κB is an important nuclear transcription factor in cells, involved in the body's inflammatory response and immune response. When excessive ultraviolet radiation and other stimuli act on the skin, it will cause NF-κB activation in keratinocytes, thereby initiating an inflammatory response. TNF-α and IL-6 are important cytokines in the early stages of inflammatory response. The expression of NF-κB in the epidermal model and the release of inflammatory factors TNF-α and IL-6 can reflect the inflammatory response of the epidermal model, thereby evaluating the soothing effect of the sample. This application is the first to test the anti-inflammatory and soothing effect of peony seed oil ceramide, and the specific experimental method is as follows:

[0057] Inhibit NF-κB expression: Take some The epidermal model was randomly divided into a blank control group, a UV irradiation group, a sample group, and a positive control group (dexamethasone). The UV irradiation group, the sample group, and the positive control group were irradiated with UVB at a dose of 50 mJ / cm 2 After the irradiation, 25 μL of sample (working concentration was 1%) was added and the saturated humidity and 5% CO 2 , 37℃ for 24h. At the end of the time, carefully rinse the surface of the model, remove the sample to be tested, wipe dry, fix it in 4% formaldehyde overnight, embed it in paraffin, slice it, and perform NF-κB immunofluorescence staining. The stained slices are placed under a fluorescence microscope and photographed, such as Figure 1 As shown, the average fluorescence intensity of NF-κB was calculated using Image J software. The NF-κB inhibition rate was calculated as follows:

[0058] NF-κB inhibition rate = average fluorescence intensity of NF-κB in the sample group - average fluorescence intensity of NF-κB in the UV irradiation group / average fluorescence intensity of NF-κB in the UV irradiation group × 100.

[0059] The results of NF-κB mean fluorescence intensity and inhibition rate are shown in Table 1.

[0060] Inhibit inflammatory factors TNF-α and IL-6: The epidermal model was randomly divided into a blank control group, a negative control group, a sample group, and a positive control group (dexamethasone). The positive control group, the negative control group, and the sample group were irradiated with UVB before adding samples, with an irradiation dose of 50 mJ / cm 2 . After the irradiation, fresh culture medium was replaced. The blank control group was not irradiated with UVB, and only the culture medium was replaced. After the irradiation, the samples were surface-administered, with a sample volume of 25 μL (working concentration of 1%), and the action time was 24 h. At the end of the time action, the culture medium of each group was collected, and after centrifugation, IL-6 and TNF-α in the culture supernatant were detected according to the instructions of the ELISA kit, and the release inhibition rate was calculated. The calculation formula is as follows:

[0061] Inhibition rate of inflammatory factors TNF-α and IL-6 = expression level of inflammatory factors in the negative control group - expression level of inflammatory factors in the sample group / expression level of inflammatory factors in the negative control group × 100.

[0062] The expression levels of IL-6 and TNF-α and their inhibition rates are shown in Table 2.

[0063] Table 1 Effect of peony seed oil ceramide on NF-κB expression

[0064] Mean fluorescence intensity Inhibition rate Blank control group 27.183±2.583 / UV irradiation group 44.451±2.884 / Positive control group 26.717±0.730 39.9％±1.6％ Peony Seed Oil Ceramide 25.112±1.266 43.5％±2.8％

[0065] From Table 1 and Figure 1 It can be seen that peony seed oil ceramide can significantly inhibit the expression of NF-κB in the UV irradiated epidermal model, thereby inhibiting the skin's inflammatory response and exerting a soothing effect.

[0066] Table 2 Effect of peony seed oil ceramide on the expression of IL-6 and TNF-α

[0067]

[0068] From the results in Table 2, it can be seen that peony seed oil ceramide can significantly inhibit the expression of TNF-α and IL-6, inhibit skin inflammatory response, improve the redness caused by skin inflammatory response, and exert a soothing effect.

[0069] In addition, the whitening effect of ceramide peony seed oil was tested in this embodiment, and the testing method included: The melanin model was randomly divided into a blank control group, a negative control group, a sample group, and a positive control group (kojic acid). The positive control group, the negative control group, and the sample group were irradiated with UVB before adding samples, with an irradiation dose of 50 mJ / cm 2 . After the irradiation, the culture medium was replaced with fresh one. The blank control group was not irradiated with UVB, and only the culture medium was replaced. The samples were surface-administered on the 6th day of gas-liquid and the 8th day of gas-liquid, with a sample volume of 25 μL (working concentration of 1%), and each action lasted for 48 hours. The sample surface was gently rinsed three times with sterile DPBS to remove the residual sample, and after wiping off the residual water, the following tests were performed:

[0070] 1) Apparent chromaticity: Place the colorimetric card in the studio, fix the SLR camera so that the model is directly below the camera, use tweezers to place a single model in the colorimetric card circle, adjust the camera parameters and take a photo. Figure 2 shown.

[0071] 2) Determination of apparent brightness L* value: Place the model on photo paper with clean tweezers, ensuring that the cuticle is facing upwards; after the colorimeter is self-calibrated, press the colorimeter detection hole vertically on the model surface and read three times, and take the average value as the final L* value reading of the single model. The calculation formula for the L* value increase rate is as follows:

[0072] L* value increase rate = L* value of sample group - L* value of negative control group / L* value of inflammatory factor expression in negative control group × 100.

[0073] The results of L* value and L* value increase rate are shown in Table 3.

[0074] Table 3 Apparent brightness L* value of peony seed oil ceramide

[0075] L* Value Rise rate Blank control group 42.1±0.1 / Negative control group 39.7±0.1 / Positive control group 44.1±0.1 11.1％±0.1％ Peony Seed Oil Ceramide 43.2±0.0 8.9％±0.0％

[0076] From Table 3, Figure 2 The results showed that compared with the negative control group, peony seed oil ceramide can significantly increase the apparent brightness L* value of the model. Compared with the blank control group model, the apparent chromaticity of the negative control group model is darker, indicating that the model has the ability to respond to external UVB irradiation and has a blackening ability. Compared with the negative control group model, the apparent chromaticity of the peony seed oil ceramide model becomes white. In summary, peony seed oil ceramide can exert a whitening effect by whitening the apparent chromaticity and significantly increasing the apparent brightness L* value.

[0077] Example 2 Preparation of the composition

[0078] The present embodiment provides whitening compositions 1#-4#, and the formulas of the whitening compositions 1#-4# are shown in Tables 4-7. The preparation method of the whitening compositions comprises: heating the raw materials of phases A and B in a water bath at 85°C, stirring until uniformly dispersed, mixing phases A and B and homogenizing at 5000rpm for 5 minutes, cooling to below 65°C, adding the premixed phase C, homogenizing at 6000rpm for 3 minutes, cooling to room temperature, adding the premixed phase D, and stirring evenly to obtain the composition.

[0079] Among them, the moisturizers are specifically glycerin and betaine, the preservatives are specifically p-hydroxyacetophenone and 1,2-hexanediol, the thickener is specifically TR-1, the emulsifier is specifically SSE-20 and SS, the oil is specifically jojoba oil and squalane, the polyol is specifically butanediol, and the neutralizer is specifically arginine. The ingredients and proportions of the moisturizers, preservatives, thickeners, emulsifiers, oils and polyols used in Tables 4-7 are the same.

[0080] Table 4 Whitening composition 1#

[0081]

[0082] Table 5 Whitening composition 2#

[0083]

[0084] Table 6 Whitening composition 3#

[0085]

[0086]

[0087] Table 7 Whitening composition 4#

[0088]

[0089] In this example, the above whitening compositions 1#-4# were used as samples, and their whitening effects were specifically tested as follows.

[0090] The test is carried out in accordance with the specific requirements of Chapter 8 Human Efficacy Evaluation Test Method 5 of the "Technical Specifications for Safety of Cosmetics" (2015 Edition) on the test method for cosmetics to remove freckles and whiten their efficacy (the first method is the test method for the removal of freckles and whiten their efficacy by ultraviolet-induced human skin darkening model), which is briefly described as follows:

[0091] Eligible subjects must be healthy men or women aged 18 to 60, with an ITA° value of 20° to 41° for the skin color of the test site, have no allergic diseases, no history of allergies to cosmetics or other topical preparations, are not pregnant or breastfeeding women, and have not participated in similar trials in the past 3 months.

[0092] UV melanin model establishment: First, the minimum erythema dose (MED) of the test site (back) of the qualified subjects was tested, and then 6 areas with an area of ​​9 cm were selected at the test site. 2 The test areas are divided into the test product area, negative control area and positive control area. The interval between each test area is 1.0 cm, and the selected area in each test area is not less than 0.5 cm 2 The blackened test area was irradiated once a day with an ultraviolet sunlight simulator at a dose of 0.75 times the MED for 4 consecutive days.

[0093] Skin color evaluation: On the 5th day after the irradiation, the skin color of each darkened test area was visually evaluated before the product was used, and the skin colorimeter and skin melanin detector were tested. The ITA° value was calculated based on the L*a*b* color space value tested by the skin colorimeter.

[0094] The calculation formula is as follows:

[0095] ITA°={arc tangent[(L*-50) / b*]}*180 / π

[0096] Melanin index (MI) was measured using a skin melanin detector, and the instrument's performance indicators met the measurement specification requirements.

[0097] Test material smearing method: Apply (2.00±0.05)mg / cm2 to the test area 2 The test product (whitening composition 1#-4#) was applied in an amount of 200 mg / kg, and no product was applied to the negative control area. The product was used twice a day for 4 consecutive weeks. The skin color of each blackened test area was visually evaluated and instrumentally tested every other week after the application of the test product, and the results were recorded. The results are shown in Tables 8 to 11. Figure 3-6 .

[0098] Table 8 Difference in skin ITA° before and after product use

[0099]

[0100] From Table 8 and Figure 3 As shown, in the fourth week of applying the test product, the ITA° difference improvement effect of whitening composition 1# and whitening composition 2# was better than that of the negative control group, with obvious whitening effect. Compared with the ITA° difference improvement effect of whitening composition 1# and whitening composition 2#, whitening composition 1#> whitening composition 2#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original whitening effect of 377.

[0101] Table 9 Difference in skin MI before and after product use

[0102]

[0103]

[0104] From Table 9 and Figure 4 As shown, in the fourth week of applying the test product, the MI difference improvement effect of whitening composition 1# and whitening composition 2# was better than that of the negative control group, with obvious whitening effect. Compared with the MI difference improvement effect of whitening composition 1# and whitening composition 2#, whitening composition 1#>whitening composition 2#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original whitening effect of 377.

[0105] In addition, in the fourth week of applying the test product, experts were asked to conduct a visual assessment of the skin color. The visual assessment was performed by dermatologists using color cards from light to dark skin tones to evaluate the skin color of each test area. The skin color improvement effects of whitening composition 1# and whitening composition 2# were better than those of the negative control group, with obvious whitening effects. Compared with the skin color improvement effects of whitening composition 1# and whitening composition 2#, whitening composition 1#> whitening composition 2#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original whitening effect of 377.

[0106] Table 10 Difference in skin ITA° before and after product use

[0107]

[0108] From Table 10 and Figure 5 As shown, in the fourth week of applying the test product, the ITA° difference improvement effect of whitening composition 3# and whitening composition 4# was better than that of the negative control group, with obvious whitening effect. Compared with the ITA° difference improvement effect of whitening composition 3# and whitening composition 4#, whitening composition 3#> whitening composition 4#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original MSH whitening effect.

[0109] Table 11 Difference in skin MI before and after product use

[0110]

[0111] From Table 11 and Figure 6 As shown, in the fourth week of applying the test product, the MI difference improvement effect of whitening composition 3# and whitening composition 4# was better than that of the negative control group, and there was a significant whitening effect. Compared with the MI difference improvement effect of whitening composition 3# and whitening composition 4#, whitening composition 3#> whitening composition 4#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original MSH whitening effect.

[0112] In addition, in the fourth week of applying the test product, experts were asked to conduct a visual evaluation of the skin color. The skin color improvement effects of whitening composition 3# and whitening composition 4# were better than those of the negative control group, showing a significant whitening effect. Compared with the skin color improvement effects of whitening composition 3# and whitening composition 4#, whitening composition 3#> whitening composition 4#, indicating that the addition of 0.5% peony seed oil ceramide can enhance the original MSH whitening effect.

[0113] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.

Claims

1. Application of peony seed oil ceramide in anti-inflammatory, soothing and / or whitening.

2. A whitening composition, characterized in that: The composition comprises peony seed oil ceramide.

3. The composition according to claim 2, characterized in that Calculated by mass percentage of the composition, the concentration of the peony seed oil ceramide is 0.1%-3%.

4. The composition according to claim 2, characterized in that The composition further comprises a whitening agent; preferably, the whitening agent is selected from one or more of phenethylresorcinol, undecylenoylphenylalanine, nicotinamide, arbutin, and VC ethyl ether; more preferably, phenethylresorcinol and undecylenoylphenylalanine; preferably, the concentration of the whitening agent is 0.1%-5% by mass percentage of the composition; preferably, 0.3%.

5. The composition according to claim 2, characterized in that The composition further comprises auxiliary materials; preferably, the auxiliary materials comprise solvents, moisturizers, preservatives, thickeners, emulsifiers, oils, neutralizers, and polyols.

6. The method for preparing the whitening composition according to any one of claims 2 to 5, characterized in that: The method comprises: heating peony seed oil ceramide at 80°C-90°C, homogenizing at 2000-5000rpm for 1-5 minutes, cooling to below 70°C, homogenizing at 3000-7000rpm for 1-5 minutes, cooling to 25°C-40°C, and adding a whitening agent; preferably, the method comprises: heating peony seed oil ceramide at 85°C, homogenizing at 5000rpm for 5 minutes, cooling to below 65°C, homogenizing at 6000rpm for 3 minutes, cooling to 25°C, and adding a whitening agent.

7. Application of peony seed oil ceramide in whitening enhancer.

8. A whitening synergist, characterized in that: The whitening enhancer comprises peony seed oil ceramide.

9. Use of the whitening enhancer according to claim 8 in improving the whitening effect of a whitening agent; preferably, the whitening agent is selected from one or more of phenethylresorcinol, undecylenoylphenylalanine, nicotinamide, arbutin, and VC ethyl ether; more preferably, phenethylresorcinol and undecylenoylphenylalanine.

10. Use of the whitening composition according to any one of claims 2 to 5 or the whitening enhancer according to claim 8 in anti-inflammatory, soothing and / or whitening.

Images